Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H12ClNO3S |
Molecular Weight | 273.736 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O
InChI
InChIKey=WEQAYVWKMWHEJO-UHFFFAOYSA-N
InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3
DescriptionSources: www.ncbi.nlm.nih.gov/mesh/68002720Curator's Comment: description was created based on several sources, including
http://www.who.int/medicines/publications/drugalerts/drug_alert53chlormezanone_serious_cutaneous_reactions.pdf |
https://www.drugbank.ca/drugs/DB01178
Sources: www.ncbi.nlm.nih.gov/mesh/68002720
Curator's Comment: description was created based on several sources, including
http://www.who.int/medicines/publications/drugalerts/drug_alert53chlormezanone_serious_cutaneous_reactions.pdf |
https://www.drugbank.ca/drugs/DB01178
Chlormezanone (TRANCOPAL®) is a non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. It binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways. Chlormezanone (TRANCOPAL®) was discontinued worldwide in 1996 by Sanofi due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis also known as Stevens-Johnson syndrome).
CNS Activity
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.62 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2399514 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORMEZANONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
164.19 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2399514 |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CHLORMEZANONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
224.93 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2399514 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORMEZANONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.14 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2399514 |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CHLORMEZANONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2399514 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORMEZANONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4 g single, oral Overdose Dose: 4 g Route: oral Route: single Dose: 4 g Co-administed with:: acetaminophen, p.o(18 g) Sources: Page: p.45 |
healthy, 46 n = 1 Health Status: healthy Age Group: 46 Sex: M Population Size: 1 Sources: Page: p.45 |
Disc. AE: Coma... AEs leading to discontinuation/dose reduction: Coma (grade 5) Sources: Page: p.45 |
400 mg 3 times / day multiple, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: Page: p.44, p.45 |
unhealthy n = 10 Health Status: unhealthy Condition: Painful muscular spasms Population Size: 10 Sources: Page: p.44, p.45 |
Disc. AE: Muscular weakness, Ataxia... AEs leading to discontinuation/dose reduction: Muscular weakness Sources: Page: p.44, p.45Ataxia Stumbling Tachycardia |
800 mg single, oral Studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: Page: p.44 |
unhealthy n = 5 Health Status: unhealthy Condition: Painful muscular spasms Population Size: 5 Sources: Page: p.44 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Coma | grade 5 Disc. AE |
4 g single, oral Overdose Dose: 4 g Route: oral Route: single Dose: 4 g Co-administed with:: acetaminophen, p.o(18 g) Sources: Page: p.45 |
healthy, 46 n = 1 Health Status: healthy Age Group: 46 Sex: M Population Size: 1 Sources: Page: p.45 |
Ataxia | Disc. AE | 400 mg 3 times / day multiple, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: Page: p.44, p.45 |
unhealthy n = 10 Health Status: unhealthy Condition: Painful muscular spasms Population Size: 10 Sources: Page: p.44, p.45 |
Muscular weakness | Disc. AE | 400 mg 3 times / day multiple, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: Page: p.44, p.45 |
unhealthy n = 10 Health Status: unhealthy Condition: Painful muscular spasms Population Size: 10 Sources: Page: p.44, p.45 |
Stumbling | Disc. AE | 400 mg 3 times / day multiple, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: Page: p.44, p.45 |
unhealthy n = 10 Health Status: unhealthy Condition: Painful muscular spasms Population Size: 10 Sources: Page: p.44, p.45 |
Tachycardia | Disc. AE | 400 mg 3 times / day multiple, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: Page: p.44, p.45 |
unhealthy n = 10 Health Status: unhealthy Condition: Painful muscular spasms Population Size: 10 Sources: Page: p.44, p.45 |
PubMed
Title | Date | PubMed |
---|---|---|
[Cleavage and biotransformation of the central muscle relaxant chlormezanone]. | 1998 Sep |
|
Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. | 2003 Jan 3 |
|
[Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome]. | 2009 Aug |
|
Flupirtine in pain management: pharmacological properties and clinical use. | 2010 Oct |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15897685
The investigation was performed in order to investigate whether the racemic chlormezanone and both enantiomers differ in their potential cytotoxicty for human HaCaT keratinocytes. In the dosage range of 0.001 to 0.1 mg/ml chlormezanone, no antiproliferative effects were measured with the racemate and both enantiomers. At 1.0 mg/ml, a decrease of proliferative activity was seen after 48 h incubation time of about 50% for the enantiomers and of about 80% for the racemate (PicoGreen assay) and 50% (enantiomers) or 21% (racemate) in the ATP assay, respectively. Oxygen radicals production by human interleukin-3-stimulated leukocytes was significantly inhibited at concentrations < or =0.01 mg/ml by the racemate and the (+)-enantiomer, whereas the (-)-enantiomer was less effective.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M03BB52
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
||
|
WHO-VATC |
QM03BB02
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
||
|
WHO-VATC |
QM03BB52
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
||
|
WHO-ATC |
M03BB72
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
||
|
WHO-VATC |
QM03BB72
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
||
|
WHO-ATC |
M03BB02
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
||
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081564
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
3619
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
CHLORMEZANONE
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
80-77-3
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
7323
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200714
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
603
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
782
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
m3376
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | Merck Index | ||
|
3300
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
169108
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
D002720
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
SUB06187MIG
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
C65316
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
201-307-4
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
2373
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | RxNorm | ||
|
2717
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
DTXSID3022798
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
DB01178
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY | |||
|
GP568V9G19
Created by
admin on Fri Dec 15 16:17:03 UTC 2023 , Edited by admin on Fri Dec 15 16:17:03 UTC 2023
|
PRIMARY |
ACTIVE MOIETY